Document is current

Article History

Received: 1 October 2025

Accepted: 17 February 2026

First Online: 9 March 2026

Declarations

:

: Karel Pavelka has received consulting fees from AbbVie, Celltrion, Eli Lilly and Company, MSD, Novartis, Pfizer, and UCB Pharma; speaker honoraria from AbbVie, Biogen, Eli Lilly and Company, Johnson and Johnson, Medac, Novartis, and Pfizer; travel support from Medac and Novartis; and has participated in monitoring or advisory boards for AbbVie, Biogen, Eli Lilly and Company, Johson and Johnson, Medac, Novartis, and Pfizer. Ladislav Šenolt has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Fresenius Kabi, GSK, Johnson & Johnson, Merck Sharp and Dohme, Novartis, Pfizer, Sanofi, Sandoz, Swedish Orphan Biovitrum, and UCB Pharma. Iva Váchová and Ewa Haladyj are employees and minor shareholders of Eli Lilly and Company. Lenka Klementová has no conflicts of interest to declare. Jana Šilarová has no conflicts of interest to declare. Jakub Závada has received speaker honoraria from AbbVie, Akord, Astra Zeneca, Celltrion, Eli Lilly and Company, GSK, Novartis, Pfizer, Sandoz, Sobi, and UCB Pharma; travel support from AbbVie, Eli Lilly and Company, Sobi, and UCB Pharma; and has participated in advisory boards for AbbVie, Astra Zeneca, and GSK. The authors would like to thank study participants and their caregivers, as well as all physicians in the Czech Republic who contribute to ATTRA.

: This study was conducted in accordance with Good Clinical Practice, the principles of the Declaration of Helsinki, and local laws and regulations in the Czech Republic. All patients provided written informed consent prior to inclusion in the registry, and permissions were obtained to access and analyse registry data.